Nestle said it has sold its Palforzia peanut-allergy treatment business to biopharmaceutical company Stallergenes Greer.
The Swiss consumer-goods company said Monday that it will receive milestone payments and royalties from Stallergenes Greer. The deal was closed upon signing, Nestle said. The sale allows Nestle's health-science operations to focus on its core strengths and key growth drivers, the unit's Chief Executive Greg Behar said.
Nestle last year said that it would conduct a strategic review of Palforzia after a slower-than-expected adoption by patients and healthcare professionals.
España Últimas Noticias, España Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Nestle divests peanut allergy business Palforzia By ReutersNestle divests peanut allergy business Palforzia
Leer más »
Nestle divests peanut allergy business PalforziaNestle has divested its peanut allergy treatment business Palforzia, the Swiss food company said on Monday, following its strategic review of the division.
Leer más »